Compare Charles River Laboratories Intl. Inc (CRL) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $228.72 (market cap $11.14B), while Virgin Galactic Holdings, Inc. trades at $2.67 (market cap $335.48M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 33.2× Virgin Galactic Holdings, Inc.'s market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CRL | SPCE | |
|---|---|---|
Market Cap | $11.14B | $335.48M |
Sector | Health | Industrials |
52-Week High | $233.60 | $7.52 |
52-Week Low | $145.57 | $2.17 |
Enterprise Value | $14.00B | $435.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SPCE trades at $2.42, down 5.84% over 24 hours, reflecting ongoing volatility amid negative profitability. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with cash burn persisting despite narrowing losses. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels, while analyst consensus is divided with a slight hold bias.
The outlook remains speculative, with opportunities tied to future commercial spaceflight execution, but risks are elevated due to persistent losses, high cash burn, and significant debt. Investor sentiment is cautious, driven by the unproven business model and competitive pressures in the space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
